Gabon seeks to shield iboga plant from commercial exploitation by US firms

A binding international agreement or domestic Gabonese law protecting iboga IP rights would likely reduce near-term biotech/pharma upside in natural product extraction but could establish a precedent that increases regulatory clarity and reduces litigation risk for companies seeking legitimate benefit-sharing partnerships.

If Gabon's protections remain symbolic or unenforced while US firms proceed with research and patenting, the status quo of fragmented IP claims would persist, creating ongoing legal ambiguity that neither substantially constrains pharma development nor delivers meaningful revenue to Gabon.

Escalation into trade disputes, patent invalidations, or coordinated African biopiracy enforcement could impose material costs on companies holding iboga-derived IP and create broader chilling effects on natural product R&D pipelines if other nations adopt similar blocking tactics.